Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259089 · ClinicalTrials.gov registry record · Phase 1
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01259089 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 38 participants.
The verdict
NCT01259089, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.
Interventions
- OTHER laboratory biomarker analysis
- GENETIC mutation analysis
- DRUG erlotinib hydrochloride
- PROCEDURE needle biopsy
- DRUG Hsp90 inhibitor AUY922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-04-27 |
| Est. Completion | 2014-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259089
The ClinicalTrials.gov registry entry for NCT01259089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01259089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01259089 about?
NCT01259089 is a clinical study titled "Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer". Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how wel...
What is the current status of trial NCT01259089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2011-04-27. Estimated completion is 2014-09-29.
What interventions are being tested in trial NCT01259089?
The interventions under investigation include: laboratory biomarker analysis (OTHER), mutation analysis (GENETIC), erlotinib hydrochloride (DRUG), needle biopsy (PROCEDURE), Hsp90 inhibitor AUY922 (DRUG).
Who is sponsoring clinical trial NCT01259089?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.